Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.
about
Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular CarcinomaAnti-inflammatory activity of a novel family of aryl ureas compounds in an endotoxin-induced airway epithelial cell injury modelUpregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma.TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma.Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapyHepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategiesProtein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinomaSurgical strategy for liver cancers in the era of effective chemotherapy.High expression of inositol polyphosphate phosphatase-like 1 associates with unfavorable survival in hepatocellular carcinomaOverexpression of Yes-associated protein and its association with clinicopathological features of hepatocellular carcinoma: A meta-analysis.Learning from practice: compulsory licensing cases and access to medicines.Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma.Inhibition of Annexin A2 gene transcription is a promising molecular target for hepatoma cell proliferation and metastasisDevelopment of a novel zebrafish xenograft model in ache mutants using liver cancer cell lines.Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: (131)I-antiAFPMcAb-GCV-BSA-NPs.
P2860
Q26782003-646AC3D4-8F79-4BF1-9B80-F6A73847A56DQ28485098-38250F81-C7A3-4BCB-A763-20DD04D61E95Q33592941-CDC8C28A-DBF9-4892-B3A5-6283CC4C4BDAQ35368917-36A305AC-2E86-4E6F-B399-E066E1A0E249Q36545796-C018C3F0-1084-4B22-BEE2-E4C47CB0B47EQ36561567-DD7BDA4B-5688-4CA2-A839-85DC942A48AAQ36952594-59942EAD-AD54-4DB1-8ACB-9FB6FACFCA1EQ37105519-226C1603-6A5C-410E-944B-1D37DEA7DA21Q37277811-23CE1870-C2CF-4BF1-B74B-FF54188E64DBQ38371893-FCC6C9FC-C358-4416-A738-84D1288AADD4Q38452135-176E29D2-8AC7-4061-919F-F52BA153DD0DQ41138780-EE0B0100-4597-44E5-BD5F-B8098580E8DFQ42056870-3BD9321A-7208-4F17-AD40-FB01DA4358AAQ42248443-3461FC46-878C-4527-9D3A-4295E8095887Q48162603-804F2E10-FB59-44E4-8705-99E2ADF3CA4BQ55190863-7AC23110-A221-4431-AA20-A9E22C6B1B27
P2860
Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Systemic treatment and targete ...... nced hepatocellular carcinoma.
@ast
Systemic treatment and targete ...... nced hepatocellular carcinoma.
@en
type
label
Systemic treatment and targete ...... nced hepatocellular carcinoma.
@ast
Systemic treatment and targete ...... nced hepatocellular carcinoma.
@en
prefLabel
Systemic treatment and targete ...... nced hepatocellular carcinoma.
@ast
Systemic treatment and targete ...... nced hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Systemic treatment and targete ...... nced hepatocellular carcinoma.
@en
P2093
Anass Touyar
El Mehdi Tazi
Hind M'rabti
Ismail Essadi
Pr Hassan Errihani
P2860
P304
P356
10.4297/NAJMS.2011.3167
P577
2011-04-01T00:00:00Z